NORCROSS, GA and HALIFAX, Feb. 1, 2012 /CNW/ - Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has signed a
definitive agreement granting CAN-med Healthcare exclusive distribution rights for LuViva® Advanced Cervical Scan in Canada.
The agreement is for three years and initial shipments are currently
anticipated in the second quarter of 2012. A formal launch is expected
to begin shortly thereafter. LuViva received Health Canada marketing
approval in December 2011 under its former name, LightTouch.
"CAN-med is a leading and greatly respected healthcare company and we
are pleased to have them as our partner in Canada," said Mark L.
Faupel, Ph.D., CEO and president of Guided Therapeutics, Inc.
"CAN-med's nation-wide reputation and commitment to women's health,
from mammography to gynecological imaging products, makes the company
ideally suited to introduce LuViva to the Canadian market and grow
"Based on LuViva's documented clinical evidence and our 35 years of
experience delivering innovations to the Canadian healthcare market, we
believe that LuViva will be well received, with an opportunity to
positively impact the lives of women at risk for developing cervical
cancer," said Jim Ritcey, Director, Sales and Marketing,
Medical/Surgical for CAN-med Healthcare. "Additionally, we believe
that LuViva will bring a new level of efficiency and cost effectiveness
to the healthcare system." Stephen McDonald, CAN-med's Vice President &
General Manager adds "Guided Therapeutics and the LuViva product are a
great match for us in bringing new products to the Canadian market.
They fit the criteria we're looking for by being clinically innovative
with new technology, being willing to develop an exclusive working
relationship, and delivering better clinical and patient outcomes."
Each year in Canada, about 5.7 million women undergo Pap test screening
for cervical cancer, with as many as 400,000 receiving an abnormal Pap
result. These women are then scheduled for a follow-up exam, called a
colposcopy, which typically includes a biopsy. The wait times for
colposcopy examinations in Canada are typically between two to six
months. LuViva is designed to reduce wait times and provide results
immediately at the point of care.
About CAN-med Healthcare
CAN-med Healthcare, a division of IMP Group Limited, is a national, integrated healthcare
distribution and service company with a portfolio of businesses
providing products and technical service spanning four distinct
segments of the healthcare market: Medical/Surgical; Diagnostic
Imaging; Rehab/Mobility/Home Medical Equipment; and Dental products.
IMP Group Limited is focused on global sustainable growth with 3,700 experienced people
delivering service, quality and value to customers across diverse
sectors including aerospace, aviation, airline, healthcare, information
technology, hospitality and property development.
About LuViva® Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the
cervix with light and uses spectroscopy to measure how light interacts
with the cervical tissue. Spectroscopy identifies chemical and
structural indicators of precancer that may be below the surface of the
cervix or misdiagnosed as benign. This technique is called
biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not
require laboratory analysis or a tissue sample, and is designed to
provide results immediately, which eliminates costly, painful and
unnecessary testing. LuViva is designed for use with women who have
undergone initial screening and are called back for follow up with a
colposcopy examination, which in many cases involves taking a biopsy of
the cervix. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) is developing a rapid
and painless testing platform for the early detection of disease based
on its patented biophotonic technology that utilizes light to detect
disease at the cellular level. The company's first planned product is
the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical
disease instantly and at the point of care. In a multi-center clinical
trial, with women at risk for cervical disease, the technology was able
to detect cervical cancer up to two years earlier than conventional
modalities, according to published reports. Guided Therapeutics has
also entered into a partnership with Konica Minolta Opto to develop a
non-invasive test for Barrett's Esophagus using the technology
platform. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by
federal law to investigational use.
LuViva and wave logo are registered trademarks of Guided Therapeutics,
Inc. "Early detection, better outcomes" is a trademark owned by Guided
Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and
developments. The discussion of such matters and subject areas is
qualified by the inherent risks and uncertainties surrounding future
expectations generally and also may materially differ from Guided
Therapeutics' actual future experience involving any of or more of such
matters and subject areas. Such risks and uncertainties include: the
early stage of products in development, the uncertainty of market
acceptance of products, the uncertainty of development or effectiveness
of distribution channels, the intense competition in the medical device
industry, the uncertainty of capital to develop products, the
uncertainty of regulatory approval of products, dependence on licensed
intellectual property, as well as those that are more fully described
from time to time under the heading "Risk Factors" in Guided
Therapeutics' reports filed with the SEC, including Guided
Therapeutics' Annual Report on Form 10-K for the fiscal year ended
December 31, 2010, and subsequent quarterly reports.
SOURCE Guided Therapeutics, Inc.
For further information:
Investors: Alison Ziegler, Cameron Associates, 212-554-5469
Bill Wells, Guided Therapeutics, 770-242-8723 Ext. 241
Jim Ritcey, Director, Sales and Marketing, Medical/Surgical, CAN-med, 902-455-4649